Yanase Komei, Funaguchi Norihiko, Iihara Hirotoshi, Yamada Maya, Kaito Daizo, Endo Junki, Ito Fumitaka, Ohno Yasushi, Tanaka Hidekazu, Itoh Yoshinori, Minatoguchi Shinya
Department of Cardiology and Respirology and Nephrology, Gifu University Graduate School of Medicine Japan.
Department of Cardiology and Respirology and Nephrology, Gifu University Graduate School of Medicine Japan ; Department of Respiratory Medicine, Murakami Memorial Hospital, Asahi University Japan.
Int J Clin Exp Med. 2015 Sep 15;8(9):16215-22. eCollection 2015.
Concurrent chemoradiotherapy (CCRT) plays an important role in multimodality therapy for non-small cell lung cancer. However, esophagitis often develops as a complication of CCRT, causing treatment delays and reducing the patient's quality of life. We examined the efficacy of polaprezinc (PZ), zinc L-carnosine used for the therapy of gastric ulcer, against the onset of esophagitis caused by CCRT for lung cancer.
Patients who concurrently underwent chemotherapy with carboplatin and paclitaxel and thoracic radiotherapy at Gifu University Hospital during a period of January 2011 and May 2015 were the subjects of the present study. Patients received a mixture of sodium alginate solution and aluminum-magnesium hydroxide gel with (PZ group) or without (control group) PZ for prevention of radiation esophagitis.
PZ significantly inhibited the development of grade ≥2 radiation esophagitis (HR 0.397, 95% confidence interval, 0.160-0.990; P=0.047). In addition, PZ lowered the incidence of grade ≥2 esophagitis at the time point of 40 Gy irradiation (26.3% versus 63.2%, P=0.05). However, there were no significant differences in the incident rates of other adverse events associated with chemoradiotherapy between the PZ group and control group. Moreover, PZ had no significant influence on the tumor response rate.
PZ significantly retarded the development as well as the incidence of grade ≥2 esophagitis without affecting the tumor response.
同步放化疗（CCRT）在非小细胞肺癌的多模式治疗中发挥着重要作用。然而，食管炎常作为CCRT的并发症出现，导致治疗延迟并降低患者生活质量。我们研究了用于治疗胃溃疡的聚普瑞锌（PZ，L-肌肽锌）对肺癌CCRT所致食管炎发作的疗效。
2011年1月至2015年5月期间在岐阜大学医院同时接受卡铂和紫杉醇化疗及胸部放疗的患者为本研究对象。患者接受藻酸钠溶液和氢氧化铝镁凝胶的混合物，其中一组（PZ组）添加PZ，另一组（对照组）不添加PZ，用于预防放射性食管炎。
PZ显著抑制了≥2级放射性食管炎的发生（风险比0.397，95%置信区间，0.160 - 0.990；P = 0.047）。此外，在40 Gy照射时间点，PZ降低了≥2级食管炎的发生率（26.3%对63.2%，P = 0.05）。然而，PZ组和对照组之间与放化疗相关的其他不良事件发生率没有显著差异。而且，PZ对肿瘤反应率没有显著影响。
PZ显著延缓了≥2级食管炎的发生及发生率，且不影响肿瘤反应。
